Sofosbuvir

Home
About
Help
History (1)
- Sofosbuvir
- See All Pages

"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.

Descriptor ID	D000069474
MeSH Number(s)	D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
Concept/Terms	Sofosbuvir Sofosbuvir 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester PSI 7977 PSI 7977 7977, PSI PSI7977 PSI-7977 GS-7977 GS-7977 GS 7977 GS7977 Sovaldi Sovaldi

Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleotides [D03.383.742.686]
Uracil Nucleotides [D03.383.742.686.850]
Uridine Monophosphate [D03.383.742.686.850.877]
Sofosbuvir [D03.383.742.686.850.877.500]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleotides [D13.695]
Pyrimidine Nucleotides [D13.695.740]
Uracil Nucleotides [D13.695.740.850]
Uridine Monophosphate [D13.695.740.850.877]
Sofosbuvir [D13.695.740.850.877.500]
Ribonucleotides [D13.695.827]
Uracil Nucleotides [D13.695.827.919]
Uridine Monophosphate [D13.695.827.919.877]
Sofosbuvir [D13.695.827.919.877.500]

Below are MeSH descriptors whose meaning is related to "Sofosbuvir".

Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.

Bar chart showing 12 publications over 6 distinct years, with a maximum of 3 publications in 2016 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	1	0	1
2015	1	1	2
2016	1	2	3
2017	0	3	3
2018	0	2	2
2021	0	1	1

Below are the most recent publications written about "Sofosbuvir" by people in Profiles.

Turgeon MK, Shah SA, Delman AM, Tran BV, Agopian VG, Wedd JP, Magliocca JF, Kim A, Cameron A, Olyaei A, Orloff SL, Anderson MP, Kubal CA, Cannon RM, Locke JE, Simpson MA, Akoad ME, Wongjirad CP, Emamaullee J, Moro A, Aucejo F, Feizpour CA, Vagefi PA, Nguyen MH, Esquivel CO, Dhanireddy K, Subramanian V, Chavarriaga A, Kazimi MM, Anderson MS, Sonnenday CJ, Kim SC, Foley DP, Abdouljoud M, Salgia RJ, Moris D, Sudan DL, Ganesh SR, Humar A, Doyle M, Chapman WC, Maithel SK. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. Ann Surg. 2021 10 01; 274(4):613-620.

View in: PubMed
Murakami N, Ding Y, Cohen DJ, Chandraker AK, Rennke HG. Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir). Transpl Infect Dis. 2018 Oct; 20(5):e12959.

View in: PubMed
Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, Alper CJ, Lenz K, Jeffrey PL. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. J Manag Care Spec Pharm. 2018 Jul; 24(7):591-597.

View in: PubMed
Lu CY, Zhang F, Golonski N, Lupton C, Jeffrey P, Wagner AK. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value Health. 2018 06; 21(6):692-697.

View in: PubMed
Spooner LM, Abraham GM. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case. Am J Health Syst Pharm. 2017 04 15; 74(8):555.

View in: PubMed
Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient. Transpl Infect Dis. 2017 Apr; 19(2).

View in: PubMed
Smith HL, Chung RT, Mantry P, Chapman W, Curry MP, Schiano TD, Boucher E, Cheslock P, Wang Y, Molrine DC. Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study. J Viral Hepat. 2017 03; 24(3):197-206.

View in: PubMed
Thokala P, Simpson EL, Tappenden P, Stevens JW, Dickinson K, Ryder S, Harrison P. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. Pharmacoeconomics. 2016 08; 34(8):741-50.

View in: PubMed
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016; 11(7):e0158431.

View in: PubMed
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb; 63(2):408-17.

View in: PubMed

People

Explore

Similar Concepts

Top Journals